Boston Scientific Corporation (BSX)
| Market Cap | 149.24B |
| Revenue (ttm) | 19.35B |
| Net Income (ttm) | 2.79B |
| Shares Out | 1.48B |
| EPS (ttm) | 1.87 |
| PE Ratio | 53.86 |
| Forward PE | 30.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,273,556 |
| Open | 100.41 |
| Previous Close | 100.57 |
| Day's Range | 99.94 - 101.15 |
| 52-Week Range | 83.38 - 109.50 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 124.53 (+23.64%) |
| Earnings Date | Oct 22, 2025 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price target is $124.53, which is an increase of 23.64% from the latest price.
News
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno...
Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy
Boston Scientific delivered strong Q3 results, with 20% revenue growth and beats on both top and bottom lines, prompting a rating upgrade to Buy. BSX's cardiovascular and MedSurg segments, driven by i...
These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings
Boston Scientific Corporation (NYSE:BSX) reported better-than-expected third-quarter results on Wednesday.
Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 8:00 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President ...
Boston Scientific lifts annual profit forecast on strong demand for heart devices
Boston Scientific raised its annual profit forecast on Wednesday, after the medical device maker beat third-quarter profit estimates on strong demand for its heart devices.
Boston Scientific Raises Outlook on Continued Cardiovascular Growth
The medical device company recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.
Boston Scientific announces results for third quarter 2025
MARLBOROUGH, Mass. , Oct. 22, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported ...
It's time to scoop up undervalued stocks in this critical sector of the economy
Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.
Boston Scientific buys Nalu Medical for $533 million
Medical device maker Boston Scientific said on Friday it will buy privately-held Nalu Medical for a cash payment of about $533 million, expanding its portfolio to address chronic pain.
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass. , Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it ...
4 Top AI-Powered Healthcare Stocks
Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthc...
Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript
Boston Scientific Corporation (NYSE:BSX) Analyst/Investor Day September 30, 2025 8:30 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President...
Top 3 Health Care Stocks That May Explode In September
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results
MARLBOROUGH, Mass. , Sept. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategi...
8 Growth Stocks to Buy That Aren't Technology. What Makes Them Worth It.
As tech stocks float at historic highs, it's a good time to look elsewhere for growth. A Citi screen turned up eight names that are mostly outside the tech sector.
Boston Scientific Corporation Is Expensive But Worth It
Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion, an...
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.
Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.
Cramer's Stop Trading: Boston Scientific
Jim Cramer breaks down why he's keeping an eye on shares of Boston Scientific.
Boston Scientific lifts annual profit view on steady heart devices demand
Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates.
Boston Scientific announces results for second quarter 2025
MARLBOROUGH, Mass. , July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported...
How To Trade Boston Scientific Stock Ahead Of Its Upcoming Earnings?
Boston Scientific (NYSE:BSX) is set to announce its earnings on Wednesday, July 23, 2025. In the last five years, BSX stock has shown a positive return on the day after earnings announcements in 60% o...

